Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name	of	entity	,

MAL	MALACHITE RESOURCES LIMITED		
ABN	75 613 268		
000,	75 013 200		
We ((the entity) give ASX the following	information.	
	t 1 - All issues nust complete the relevant sections (attach	sheets if there is not enough space).	
1	*Class of *securities issued or to be issued	Series B Convertible Notes	

Number of *securities issued or to be issued (if known) or maximum number which may be issued 18 Convertible Notes issued
7 Convertible Notes to be issued subject to shareholder approval

04/03/2013 Appendix 3B Page 1

⁺ See chapter 19 for defined terms.

Principal terms of the 3 +securities (e.g. if options, exercise price and expiry date; if paid +securities, amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

Issue Price	\$10,000
Per Note	ψ10,000
Maturity Date	31 August 2018
Interest Rate	15.00% per annum until the Maturity Date payable in arrears on the last day of each quarter.
Conversion Price	(i) if 80% of the 30 Day VWAP immediately prior to the Conversion Date is less than \$0.003; or (ii) if 80% of the 30 Day VWAP immediately prior to the Conversion Date is greater than \$0.003 and less than \$0.006, then 80% of the 30 Day VWAP; or (iii) if 80% of the 30 Day VWAP immediately prior to the Conversion Date is greater than \$0.006, then \$0.006.
Convertibility	The Notes may be converted into fully paid ordinary shares in the capital of the Company at any time following the issue of the Notes at the election of the Noteholder subject to all requisite regulatory and shareholder approvals if required.
Security	The Notes are unsecured.

4 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

	T			. 1	
5	Issue	price	or	consid	eration

\$10,000 per Convertible Note	

0	(If issued as consideration for the acquisition of assets, clearly identify those assets)	Issued for ongoing working capital purposes.
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	Yes
6b	The date the security holder resolution under rule 7.1A was passed	Shareholder approval obtained at Annual General Meeting held on 29 November 2016.
6c	Number of *securities issued without security holder approval under rule 7.1	18 Convertible Notes issued 7 Convertible Notes to be issued subject to shareholder approval
		In the event that all 18 Convertible Notes were converted to shares at the minimum price of \$0.003 the Company would be required to issue 60,000,000 shares
6d	Number of *securities issued with security holder approval under rule 7.1A	11,526,223 - 7 December 2016
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil
6f	Number of *securities issued under an exception in rule 7.2	Nil
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	-

o4/o3/2013 Appendix 3B Page 3

⁺ See chapter 19 for defined terms.

6h If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

Issued Capital: 1,298,041,044 25% Capacity: 324,510,261 Capacity Consumed if all 18 Convertible Notes were converted to shares at the minimum price of \$0.003: 60,000,000 Remaining Capacity (if all 18 Convertible Noted converted): 264,510,261

18 October 2017

7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

8 Number and ⁺class of all ⁺securities quoted on ASX (*including* the ⁺securities in section 2 if applicable)

in a th		
	Number	+Class
ll X n	1,298,041,044	MAR Shares

9 Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)

Number	+Class
43	Convertible Notes: Each note has a face value of \$50,000 convertible at the lower of a 20% discount to the 30 day VWAP or \$0.015, term to 1 October 2018 (extension of term is subject to shareholder approval at AGM to be held on 29 November 2017), Interest Rate of 15% per annum.
18 issued 7 to be issued subject to shareholder approval	Series B Convertible Notes: Each note has a face value of \$10,000, convertible at not less than \$0.003 and not more than \$0.006, term to 31 August 2018, Interest Rate of 15% per annum.

10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	No change
Part	2 - Pro rata issue	
11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the *securities will be offered	
14	⁺ Class of ⁺ securities to which the offer relates	
15	⁺ Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has security holders who will not be sent new offer documents	
	Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	

04/03/2013 Appendix 3B Page 5

⁺ See chapter 19 for defined terms.

24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do security holders sell their entitlements <i>in full</i> through a broker?	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	
32	How do security holders dispose of their entitlements (except by sale through a broker)?	
33	⁺ Issue date	
	3 - Quotation of securities ed only complete this section if you are app	
34	Type of *securities (tick one)	
(a)	*Securities described in Part 1	I.
(b)	*	d of the escrowed period, partly paid securities that become fully paid, restriction ends, securities issued on expiry or conversion of convertible
	securities	restriction chas, securities issued on expiry of conversion of convertible

Entities that have ticked box 34(a) Additional securities forming a new class of securities

lick to locum	ents	ion or	
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders		
36	If the +securities are +equity +securities setting out the nu 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over		
37	A copy of any trust deed for	the additional ⁺ securities	
Entiti	es that have ticked box 34(b)		
38	Number of *securities for which *quotation is sought		
39	⁺ Class of ⁺ securities for which quotation is sought		
40	Do the ⁺ securities rank equally in all respects from the ⁺ issue date with an existing ⁺ class of quoted ⁺ securities?		
	If the additional ⁺ securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment		
	• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now		
	Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another +security, clearly identify that other +security)		
		Number	+Class
42	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the ⁺ securities in clause 38)		

04/03/2013 Appendix 3B Page 7

⁺ See chapter 19 for defined terms.

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the ⁺securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those +securities should not be granted +quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before ⁺quotation of the ⁺securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 19 October 2017 (Director/Company secretary)

Print name: Andrew J. Cooke

== == == ==